» Articles » PMID: 8873138

Muscarinic Antagonists Microinjected into the Subthalamic Nucleus Decrease Muscular Rigidity in Reserpinized Rats

Overview
Journal Neurosci Lett
Specialty Neurology
Date 1996 Aug 9
PMID 8873138
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of anticholinergic agents microinjected into the subthalamic nucleus to reduce reserpine-induced muscular rigidity was assessed in rats. The electromyographical activity of the gastrocnemius-soleus muscle was used as a parameter of muscular rigidity. Reserpine (5 mg/kg i.p.) produced the appearance of electromyographical activity. The muscarinic antagonists M3 (1.27 nmol of 4-DAMP) and M1 (2.36 nmol of pirenzepine) markedly reduced the reserpine-induced electromyographical activity, whereas the M2 antagonist AFDX-116 (2.37 nmol) had no effect. These results suggest that a high cholinergic tone in the subthalamic nucleus is associated with the reserpine-induced muscular rigidity. Moreover, the M3 muscarinic antagonist is more effective than the M1 muscarinic antagonist in reducing the muscular rigidity in reserpinized rats, a model of Parkinson's disease, by blocking the high cholinergic tone in the subthalamic nucleus.

Citing Articles

Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.

Xiang Z, Thompson A, Jones C, Lindsley C, Conn P J Pharmacol Exp Ther. 2011; 340(3):595-603.

PMID: 22135383 PMC: 3286317. DOI: 10.1124/jpet.111.187856.


Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum.

Shimo Y, Wichmann T Eur J Neurosci. 2008; 29(1):104-13.

PMID: 19087163 PMC: 2719830. DOI: 10.1111/j.1460-9568.2008.06565.x.